SCHEMBL3450855

SCHEMBL3450855

OC1CCN(c2cc(-c3ccccc3)nc(-n3ccc4ccccc43)n2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.42
MAPT P10636 5/20 0.42
KMT2A Q03164 3/20 0.42
LMNA P02545 3/20 0.42
KDM4E B2RXH2 3/20 0.42
MEN1 O00255 2/20 0.42
ALDH1A1 P00352 2/20 0.42
GLA P06280 2/20 0.42
POLB P06746 2/20 0.42
GAA P10253 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PIK3CA P42336 1/20 0.41
MAPK8 P45983 1/20 0.41
MAPK9 P45984 1/20 0.41
MAPK10 P53779 1/20 0.41
TSHR P16473 3/20 0.41
HSD17B10 Q99714 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
MAPK1 P28482 1/20 0.41
USP2 O75604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3452659 0.91 MAPK8 (0.43) HPGDMAPTKMT2ALMNAKDM4E
SCHEMBL3452146 0.82 HPGD (0.47) HPGDMAPTKMT2ALMNAKDM4E
SCHEMBL3451133 0.78 HPGD (0.68) HPGDMAPTKMT2ALMNAKDM4E
SCHEMBL3451175 0.76 HPGD (0.56) HPGDMAPTKMT2ALMNAKDM4E
SCHEMBL3452044 0.75 KMT2A (0.51) HPGDMAPTKMT2ALMNAKDM4E
SCHEMBL3451651 0.71 MAPT (0.61) HPGDMAPTKMT2ALMNAKDM4E
SCHEMBL3452164 0.71 HRH4 (0.48) HPGDMAPTKMT2ALMNAKDM4E
SCHEMBL3451637 0.70 HPGD (0.50) HPGDMAPTKMT2ALMNAKDM4E
SCHEMBL22648996 0.70 BIRC5 (0.50) HPGDMAPTKMT2AMEN1ALDH1A1
SCHEMBL3450492 0.68 HRH4 (0.45) HPGDMAPTKMT2ALMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1796673-A2 NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM Reddy US Therapeutics, Inc. (US) 2007-06-20 EP claimed
US-20060084645-A1 Novel pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 US claimed
WO-2006034473-A2 NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS, INC. (US) 2006-03-30 WO claimed
US-7820654-B2 Pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2010-10-26 US disclosed
US-7820654-B2 Pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2010-10-26 US disclosed
US-7820654-B2 Pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2010-10-26 US disclosed
US-20060084645-A1 Novel pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084645-A1 Novel pyrimidine compounds, process for their preparation and compositions containing them UMPS, DPYD, TYMS HPGD 924/4885MAPT 4276/4885KMT2A 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.